{"id":124,"date":"2023-09-05T20:06:36","date_gmt":"2023-09-05T20:06:36","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?page_id=124"},"modified":"2025-01-29T21:28:09","modified_gmt":"2025-01-29T21:28:09","slug":"news","status":"publish","type":"page","link":"https:\/\/onltherapeutics.com\/test\/news\/","title":{"rendered":"News"},"content":{"rendered":"\n<div class=\"wp-block-cover alignfull is-light has-parallax wp-duotone-rgb13442188-rgb023735-1\" style=\"border-radius:40px;min-height:180px;aspect-ratio:unset;\"><span aria-hidden=\"true\" class=\"wp-block-cover__background has-background-dim-0 has-background-dim\"><\/span><div class=\"wp-block-cover__image-background wp-image-1806 has-parallax\" style=\"background-position:50% 50%;background-image:url(https:\/\/onltherapeutics.com\/test\/wp-content\/uploads\/2024\/01\/Banner_Cones_close2.png)\"><\/div><div class=\"wp-block-cover__inner-container has-global-padding is-layout-constrained wp-container-core-cover-is-layout-704e782a wp-block-cover-is-layout-constrained\">\n<p class=\"has-text-align-left has-base-color has-text-color has-link-color wp-elements-dd9fe29fa30ab137d4d596d37aa802c1\" style=\"padding-left:60px;font-size:clamp(2.2rem, 2.2rem + ((1vw - 0.2rem) * 4.235), 4rem);font-style:normal;font-weight:700;text-transform:none\">News<\/p>\n<\/div><\/div>\n\n\n\n<div style=\"height:90px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-query onl-latest-posts is-layout-flow wp-block-query-is-layout-flow\"><ul class=\"wp-block-post-template is-layout-flow wp-block-post-template-is-layout-flow\"><li class=\"wp-block-post post-2801 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n<h2 style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.765), 1.2rem);font-style:normal;font-weight:700; margin-top:0px;margin-bottom:3px;\" class=\"has-link-color wp-elements-64a7d2a13fe98e67f3f491ffc0216d0b wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2026\/03\/16\/onl-therapeutics-announces-first-european-patient-randomized-in-its-global-phase-2-galaxy-trial-of-xelafaslatide-onl1204-in-patients-with-geographic-atrophy-ga-associated-with-dry-amd\/\" target=\"_self\" >ONL Therapeutics Announces First European Patient Randomized in its Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD<\/a><\/h2>\n\n<div style=\"margin-bottom:35px;\" class=\"wp-block-post-date\"><time datetime=\"2026-03-16T07:49:00+00:00\">March 16, 2026<\/time><\/div>\n<\/li><li class=\"wp-block-post post-2641 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n<h2 style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.765), 1.2rem);font-style:normal;font-weight:700; margin-top:0px;margin-bottom:3px;\" class=\"has-link-color wp-elements-64a7d2a13fe98e67f3f491ffc0216d0b wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2025\/12\/09\/onl-therapeutics-announces-publication-of-data-from-phase-1b-study-of-xelafaslatide-an-investigational-therapy-for-geographic-atrophy-in-ophthalmology-science\/\" target=\"_self\" >ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science<\/a><\/h2>\n\n<div style=\"margin-bottom:35px;\" class=\"wp-block-post-date\"><time datetime=\"2025-12-09T03:38:39+00:00\">December 9, 2025<\/time><\/div>\n<\/li><li class=\"wp-block-post post-2608 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n<h2 style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.765), 1.2rem);font-style:normal;font-weight:700; margin-top:0px;margin-bottom:3px;\" class=\"has-link-color wp-elements-64a7d2a13fe98e67f3f491ffc0216d0b wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2025\/11\/10\/onl-therapeutics-to-present-at-eyenovate-and-the-floretina-icoor-congress-2025\/\" target=\"_self\" >ONL Therapeutics to Present at EYENOVATE and the FLORetina\u2013ICOOR Congress 2025<\/a><\/h2>\n\n<div style=\"margin-bottom:35px;\" class=\"wp-block-post-date\"><time datetime=\"2025-11-10T07:00:00+00:00\">November 10, 2025<\/time><\/div>\n<\/li><li class=\"wp-block-post post-2524 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n<h2 style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.765), 1.2rem);font-style:normal;font-weight:700; margin-top:0px;margin-bottom:3px;\" class=\"has-link-color wp-elements-64a7d2a13fe98e67f3f491ffc0216d0b wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2025\/10\/28\/onl-therapeutics-announces-randomization-of-first-patient-in-global-phase-2-galaxy-trial-of-xelafaslatide-onl1204-in-patients-with-geographic-atrophy-ga-associated-with-dry-amd\/\" target=\"_self\" >ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD<\/a><\/h2>\n\n<div style=\"margin-bottom:35px;\" class=\"wp-block-post-date\"><time datetime=\"2025-10-28T07:00:00+00:00\">October 28, 2025<\/time><\/div>\n<\/li><li class=\"wp-block-post post-2222 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n<h2 style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.765), 1.2rem);font-style:normal;font-weight:700; margin-top:0px;margin-bottom:3px;\" class=\"has-link-color wp-elements-64a7d2a13fe98e67f3f491ffc0216d0b wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2025\/02\/04\/onl-therapeutics-announces-multiple-presentations-at-leading-ophthalmology-meetings\/\" target=\"_self\" >ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings<\/a><\/h2>\n\n<div style=\"margin-bottom:35px;\" class=\"wp-block-post-date\"><time datetime=\"2025-02-04T12:00:49+00:00\">February 4, 2025<\/time><\/div>\n<\/li><li class=\"wp-block-post post-2197 post type-post status-publish format-standard hentry category-news\">\n<h2 style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.765), 1.2rem);font-style:normal;font-weight:700; margin-top:0px;margin-bottom:3px;\" class=\"has-link-color wp-elements-64a7d2a13fe98e67f3f491ffc0216d0b wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2025\/01\/07\/onl-therapeutics-appoints-penny-fleck-as-chief-development-officer\/\" target=\"_self\" >ONL Therapeutics Appoints Penny Fleck as Chief Development Officer<\/a><\/h2>\n\n<div style=\"margin-bottom:35px;\" class=\"wp-block-post-date\"><time datetime=\"2025-01-07T12:00:07+00:00\">January 7, 2025<\/time><\/div>\n<\/li><li class=\"wp-block-post post-1920 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n<h2 style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.765), 1.2rem);font-style:normal;font-weight:700; margin-top:0px;margin-bottom:3px;\" class=\"has-link-color wp-elements-64a7d2a13fe98e67f3f491ffc0216d0b wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2024\/09\/13\/onl-therapeutics-closes-65-million-in-oversubscribed-series-d-financing\/\" target=\"_self\" >ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing<\/a><\/h2>\n\n<div style=\"margin-bottom:35px;\" class=\"wp-block-post-date\"><time datetime=\"2024-09-13T11:00:38+00:00\">September 13, 2024<\/time><\/div>\n<\/li><li class=\"wp-block-post post-1900 post type-post status-publish format-standard hentry category-news\">\n<h2 style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.765), 1.2rem);font-style:normal;font-weight:700; margin-top:0px;margin-bottom:3px;\" class=\"has-link-color wp-elements-64a7d2a13fe98e67f3f491ffc0216d0b wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2024\/09\/10\/onl-therapeutics-to-present-at-the-57th-annual-scientific-meeting-of-the-retina-society-and-euretina-innovation-spotlight\/\" target=\"_self\" >ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight<\/a><\/h2>\n\n<div style=\"margin-bottom:35px;\" class=\"wp-block-post-date\"><time datetime=\"2024-09-10T11:00:54+00:00\">September 10, 2024<\/time><\/div>\n<\/li><li class=\"wp-block-post post-1827 post type-post status-publish format-standard hentry category-news category-onl-therapeutics-news\">\n<h2 style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.765), 1.2rem);font-style:normal;font-weight:700; margin-top:0px;margin-bottom:3px;\" class=\"has-link-color wp-elements-64a7d2a13fe98e67f3f491ffc0216d0b wp-block-post-title\"><a href=\"https:\/\/onltherapeutics.com\/test\/2024\/02\/06\/onl-therapeutics-to-present-at-2024-bio-ceo-investor-conference\/\" target=\"_self\" >ONL Therapeutics To Present At 2024 BIO CEO &amp; Investor Conference<\/a><\/h2>\n\n<div style=\"margin-bottom:35px;\" class=\"wp-block-post-date\"><time datetime=\"2024-02-06T12:03:57+00:00\">February 6, 2024<\/time><\/div>\n<\/li><\/ul>\n\n<nav class=\"has-link-color wp-elements-704df16aab8af237bbe297ddb59ee3fc wp-block-query-pagination has-small-font-size is-content-justification-center is-layout-flex wp-container-core-query-pagination-is-layout-a89b3969 wp-block-query-pagination-is-layout-flex\" aria-label=\"Pagination\">\n\n\n<div class=\"wp-block-query-pagination-numbers\"><span aria-current=\"page\" class=\"page-numbers current\">1<\/span>\n<a class=\"page-numbers\" href=\"?query-19-page=2\">2<\/a>\n<a class=\"page-numbers\" href=\"?query-19-page=3\">3<\/a>\n<span class=\"page-numbers dots\">&hellip;<\/span>\n<a class=\"page-numbers\" href=\"?query-19-page=5\">5<\/a><\/div>\n\n<a href=\"\/test\/wp-json\/wp\/v2\/pages\/124?query-19-page=2\" class=\"wp-block-query-pagination-next\" aria-label=\"Next Page\"><span class='wp-block-query-pagination-next-arrow is-arrow-arrow' aria-hidden='true'>\u2192<\/span><\/a>\n<\/nav><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"blank","meta":{"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-124","page","type-page","status-publish","hentry"],"featured_image_urls_v2":{"full":"","thumbnail":"","medium":"","medium_large":"","large":"","1536x1536":"","2048x2048":"","gform-image-choice-sm":"","gform-image-choice-md":"","gform-image-choice-lg":""},"post_excerpt_stackable_v2":"<p>News ONL Therapeutics Announces First European Patient Randomized in its Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD March 16, 2026 ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science December 9, 2025 ONL Therapeutics to Present at EYENOVATE and the FLORetina\u2013ICOOR Congress 2025 November 10, 2025 ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD October 28, 2025 ONL Therapeutics&hellip;<\/p>\n","category_list_v2":"","author_info_v2":{"name":"theo@myriadweb.com","url":"https:\/\/onltherapeutics.com\/test\/author\/theomyriadweb-com\/"},"comments_num_v2":"0 comments","_links":{"self":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/comments?post=124"}],"version-history":[{"count":31,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/124\/revisions"}],"predecessor-version":[{"id":2242,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/124\/revisions\/2242"}],"wp:attachment":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/media?parent=124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}